

SESSIONE 1: CAR-T e LBCL: dove siamo e dove andiamo

Real World in seconda linea

Maria Chiara Tisi
UOC Ematologia, Vicenza

CAR-T:

**e la storia continua...
migliorando**

Verona, 11 novembre 2024

Hotel Indigo Verona – Grand Hotel Des Arts




Conflitto di interessi MARIA CHIARA TISI

Company name	Research support	Employee	Consultant	Stockholder	Speakers bureau	Advisory board	Other
Gilead Science					X	X	
Novartis					X	X	
BMS					X	X	
Roche					X	X	
Incyte					X	x	
Lilly					X		
Janssen					X		
SOBI					X		
Beigene					x	x	




REAL WORLD DATA OF AXI-CEL AS SECOND FOR LARGE B CELL LYMPHOMA: RESULTS FROM DESCAR-T REGISTRY



Brisou et al, Abst 5138, ASH 2023



DESCAR-T REGISTRY: TIME FROM DECISION TO INFUSION



Brisou et al, Abst 5138, ASH 2023



DESCAR-T REGISTRY: patients characteristics

	Patients traités N=201 (87.4%)		Patients non traités N=29 (12.6%)	
Sexe masculin	122	(60.7%)	16	(55.2%)
Age	Median (min; max)		65 (34;80)	
Age >= 65 ans	77	(38.3%)	15	(51.7%)
Bridging therapy	177	(88.1%)	18	(62.1%)
ECOG	0-1		14 (48.3%)	
	164	(81.6%)	3	(10.3%)
	10	(5.0%)	12	(41.4%)
	27	(13.4%)		
LDH > Normal	No		16 (55.2%)	
	75	(37.3%)	12	(41.4%)
	122	(60.7%)	1	(3.4%)
	4	(2.0%)		
Stade Ann Arbor	I-II		4 (13.8%)	
	30	(14.9%)	20	(69.0%)
	149	(74.1%)	5	(17.2%)
	22	(10.9%)		
Histologie	LBCL		22 (75.9%)	
	149	(74.1%)	6	(20.7%)
	28	(13.9%)	0	(0.0%)
	6	(3.0%)	1	(3.4%)
	8	(4.0%)	0	(0.0%)
	10	(5.0%)		
Maladie primo-réfractaire	149	(74.1%)	23	(79.3%)


Brisou et al, Abst 5138, ASH 2023



DESCAR-T REGISTRY: bridging therapy

Bridging therapy	177	(88.1%)
Number of bridging lines		
1	153	(86.4%)
2	19	(10.7%)
3	4	(2.3%)
4	1	(0.6%)
Type of treatment*		
Monoclonal antibody	155	(87.6%)
Anti-CD20	153	(86.4%)
Chemotherapy	162	(91.5%)
Platine-based regimen	124	(70.1%)
Radiotherapy	14	(7.9%)
IMiD	11	(6.2%)
Kinase inhibitor	14	(7.9%)
Corticosteroids	13	(7.3%)


* Several treatment possible



Brisou et al, Abst 5138, ASH 2023




DESCAR-T REGISTRY: outcome



Response evaluation
N=160

BEST RESPONSE




	n	%
Complete Response	106	66.3
Partial Response	35	21.9
Stable Disease	5	3.1
Progressive Disease	11	6.9
Dead	3	1.9

Brisou et al, Abst 5138, ASH 2023



DESCAR-T REGISTRY: kinetics of responses




Brisou et al, Abst 5138, ASH 2023




DESCAR-T REGISTRY: survival

Overall survival according to treatment set
Since treatment decision



	No. of Subjects	Event	Censored	Median Survival (95%CL)
Treated set	201	12.4 % (25)	87.6 % (176)	11.1 (8.9 ; 11.1)
Untreated set	29	44.8 % (13)	55.2 % (16)	2.9 (2 ; 6.7)

PFS since CAR-T infusion




No. of Subjects	Event	Censored	Median Survival (95%CL)
201	27.9 % (56)	72.1 % (145)	6.1 (5.3 ; NA)

Brisou et al, Abst 5138, ASH 2023



DESCAR-T REGISTRY: safety




N=189		
Cytokine release syndrome	175	(92.6%)
Grade 1-2	166	(87.8%)
Grade 3-4	8	(4.2%)
Grade 5	1	(0.5%)
Neurotoxicity	82	(43.4%)
Grade 1-2	58	(30.7%)
Grade 3-4	23	(12.2%)
Grade 5	1	(0.5%)
Patients with CRS and Neurotoxicity	80	(42.3%)
Treatment received for toxicities		
Yes	140	(80.0%)
More than one	94	(67.1%)
Intensive care unit	44	(25.1%)
Median number of days (min;max)	5.0 (1 ; 25)	
Pressor amines use	8	(4.6%)
Mechanical ventilation	7	(4.0%)
Tocilizumab use	126	(72.0%)
Median days of treatment (min;max)	2.0 (1 ; 7)	
Corticosteroid use	99	(56.6%)
Siltuximab use	4	(2.3%)
Anti-IL1: Anakinra	22	(12.6%)
Anticonvulsant use	30	(17.1%)

Brisou et al, Abst 5138, ASH 2023



DESCAR-T REGISTRY: safety


Medically significant infection observed (n; %)



- Most of these infections occurred during the first month post infusion
- Only 6 bacterial, 1 viral and 1 fungal infections occurred later



Causes of death



DESCAR-T REGISTRY: comparison with clinical trial

Cohorte	ZUMA-7	ALYCANTE	DESCAR-T L2
nombre de patients	180	69	230
patients infusés	170	62	201
Drop out (%)	5,6	10,1	12,6
Age médian (Range)	58 (21;80)	70 (49-81)	61 (21-82)
stade III IV (%)	77%	74,20%	74%
Réfractaire primaire (%)	74%	54,80%	74,10%
Bridging therapy (%)	0	83,90%	88%
Suivi médian (mois)	47,2	12	3
Meilleure réponse globale (%)	83%	90%	88,20%
RC (%)	65%	71%	66,30%
CRS gr 3/4 (%)	6%	8,10%	4,20%
ICANS gr 3/4 (%)	21%	14,50%	12,20%
ref	Locke et al. NEJM 2022; Westin et al. NEJM 2023	Houot et al. Nat Med 2023	Brisou et al. ASH 2023

CART-T Team Vicenza Ematologia

Maria Chiara Tisi

Marcello Riva

Carlo Borghero

Francesca Elice

Albana Lico

Michele Wieczorek

Alberto Tosetto

Sabrina Carboniero (inf coord)

Aferesi

Manuela Rigno

Gabriella Errigo

Monica Castelli

Laboratorio di Manip e Criopr

Chiara Lievore

Cinzia Tagliaferri

Monica Mantia

Farmacia

Valentina Tabelli

Stefania Pretto

Giulia Franchin

Anna Radin

Neurologia

Giulia Zarantonello

Luigi Zuliani

Federica Ranzato

Rianimazione

Vinicio Danzi

Marina Alessandra Martin

Cardiologia

Carla Marotta

Malattie Infettive

Vinicio Manfrin

**Collegi dei centri referral,
Infermieri Professionali dell'ematologia e
tutti i pazienti e le loro famiglie**



REGIONE DEL VENETO



ULSS8
BERICA

